Compugen Cuts Q3 Loss

The firm reported no revenues for the quarter, as it seeks to advance its drug programs beyond proof of concept.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories